Brand name · Testosterone cypionate
Depo-Testosterone: adverse event reports filed with FDA
2,787 reports list it as a suspect or interacting product, 2004–2026. Class: Androgen.
- 2,787
- reports as suspect product
- 0% of all reports · about 125 a year
- 10
- reports, 12 months to June 2026
- 10 in the 12 months before
- 80.1%
- marked serious by the reporter
- 61.2% across the class
- 6.3%
- record death among outcomes, as reported
- 176 reports · not verified by FDA
Between March 2004 and May 2026, 2,787 adverse event reports received by FDA list the brand name Depo-Testosterone (testosterone cypionate) as a suspect or interacting product. Reports that mention it only as a concomitant medication (493) are left out of every figure here.
In the 12 months to June 2026, 10 reports listed it, close to the 10 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 125 reports a year and 0% of the 20,646,523 reports in the database, and 13.7% of the reports for the androgen class. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are myocardial infarction (29%), cerebrovascular accident (21.1%) and deep vein thrombosis (19.2%). A report can list several reactions, so shares add to more than 100%; 414 different terms appear across these reports. Myocardial infarction is recorded in 29% of these reports, a larger share than in the median androgen drug (3.8%).
80.1% of the reports are marked serious by the reporter (61.2% across the class); 6.3% record death among the outcomes and 50.8% record hospitalisation, as reported. 69.9% of the reports came from other health professionals, and the largest patient age group is 45 to 64 (37.7%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Depo-Testosterone reports recording the termmedian drug in androgen
- Myocardial infarctionheart attack29%808
- Cerebrovascular accidentstroke21.1%587
- Deep vein thrombosisa blood clot in a deep vein19.2%536
- Pulmonary embolisma blood clot in the lung16.5%461
- Thrombosis10.5%292
- Painpain, site not specified7.7%214
- Cardiovascular disorder7.5%210
- Anxietyanxiety6.7%188
- Cardiac failure congestivecongestive heart failure6%168
- Drug ineffectivethe medicine did not work as expected5.6%157
- Acute myocardial infarction5.6%156
- Infarction4.6%127
- Ischaemia4.5%125
- Cardiac disorder4.4%122
- Quality of life decreasedreduced quality of life4.3%119
- Coronary artery disease3.3%92
- Astheniaweakness or lack of energy3%84
- Depressionlow mood3%84
- Dyspnoeashortness of breath2.8%79
- Fatiguetiredness2.8%79
- Chest painchest pain2.6%73
- Injection site painpain where the injection was given2.3%65
- Product quality issuea problem with the product itself2.3%63
- Hypertensionhigh blood pressure1.9%53
- Atrial fibrillationan irregular heart rhythm1.9%52
- Product deposit1.9%52
- Amnesiamemory loss1.7%48
Top 30 of 414 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 8 drugs in the androgen class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,367 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 99% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Hormone replacement therapy | 896 | 32.1% |
| Androgen replacement therapy | 607 | 21.8% |
| Blood testosterone decreased | 424 | 15.2% |
| Asthenia | 54 | 1.9% |
| Fatigue | 46 | 1.7% |
| Hypogonadism | 41 | 1.5% |
The indication field is filled in by the reporter and is often blank; shares are of all 2,787 reports.
In context
| Measure | Depo-Testosterone | Androgen | All reports |
|---|---|---|---|
| Reports as suspect product | 2,787 | 20,367 | 20,646,523 |
| Share of that pool | — | 13.7% | 0% |
| Reports, latest 12 months | 10 | — | 1,332,454 |
| Marked serious | 80.1% | 61.2% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 63 | 52 | 91 |
| Hospitalisation recorded, per 1,000 reports | 508 | 295 | 213 |
| Consumer-filed share | 16.7% | 34.6% | 45.8% |
| Top term, share of reports | Myocardial infarction 29% | median 3.8% | 0.8% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the androgen class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Testosterone | generic | 7,072 | 778 | 55.9% |
| Testosterone cypionate | generic | 3,098 | 322 | 39.5% |
| Testim | brand | 3,085 | 4 | 86.9% |
| Testopel | brand | 1,442 | 21 | 70.8% |
| Aveed | brand | 1,290 | 108 | 57.9% |
| Xyosted | brand | 980 | 240 | 2.7% |
| Danazol | generic | 613 | 41 | 93.8% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Depo-Testosterone reports
How many adverse event reports has FDA received for Depo-Testosterone?
2,787 reports list Depo-Testosterone as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 10 of them arrived in the latest 12 months. Another 493 list it only as a concomitant medication.
What reactions are recorded in Depo-Testosterone reports?
myocardial infarction (29%), cerebrovascular accident (21.1%), deep vein thrombosis (19.2%), pulmonary embolism (16.5%) and thrombosis (10.5%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Depo-Testosterone was responsible.
How serious are the reports?
80.1% are marked serious by the reporter. Among the outcomes recorded, 6.3% of reports include death and 50.8% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
lawyer (69.9%), consumer or non-health professional (16.7%) and pharmacist (4.8%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Depo-Testosterone rising?
10 reports in the 12 months to June 2026, close to the 10 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Depo-Testosterone was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Depo-Testosterone?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Depo-Testosterone as a suspect or interacting product; reports listing it only as a concomitant medication (493) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.